Drug Profile
TEG 001
Alternative Names: TEG-001Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Gadeta
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Netherlands (Parenteral, Infusion)
- 02 Oct 2023 Gadeta has been acquired by Clade Therapeutics
- 28 Jan 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Netherlands (Parenteral, Infusion)